Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.

TitleNeurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.
Publication TypeJournal Article
Year of Publication2010
AuthorsRobertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, Skiest DJ
Corporate AuthorsA5170 Study Team
JournalNeurology
Volume74
Issue16
Pagination1260-6
Date Published2010 Apr 20
ISSN1526-632X
KeywordsAcquired Immunodeficiency Syndrome, Adult, AIDS Dementia Complex, Anti-Retroviral Agents, Antiretroviral Therapy, Highly Active, Brain, CD4 Lymphocyte Count, Cognition Disorders, Cohort Studies, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Prospective Studies, Recovery of Function, Risk Assessment, Viremia, Withholding Treatment
Abstract

OBJECTIVE: Prior studies have shown improved neurocognition with initiation of antiretroviral treatment (ART) in HIV. We hypothesized that stopping ART would be associated with poorer neurocognitive function.

METHODS: Neurocognitive function was assessed as part of ACTG 5170, a multicenter, prospective observational study of HIV-infected subjects who elected to discontinue ART. Eligible subjects had CD4 count >350 cells/mm(3), had HIV RNA viral load <55,000 cp/mL, and were on ART (>or=2 drugs) for >or=6 months. Subjects stopped ART at study entry and were followed for 96 weeks with a neurocognitive examination.

RESULTS: A total of 167 subjects enrolled with a median nadir CD4 of 436 cells/mm(3) and 4.5 median years on ART. Significant improvements in mean neuropsychological scores of 0.22, 0.39, 0.53, and 0.74 were found at weeks 24, 48, 72, and 96 (all p < 0.001). In the 46 subjects who restarted ART prior to week 96, no significant changes in neurocognitive function were observed.

CONCLUSION: Subjects with preserved immune function found that neurocognition improved significantly following antiretroviral treatment (ART) discontinuation. The balance between the neurocognitive cost of untreated HIV viremia and the possible toxicities of ART require consideration.

CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that discontinuing ART is associated with an improvement in 2 neuropsychological tests (Trail-Making Test A & B and the Wechsler Adult Intelligence Scale-Revised Digit Symbol subtest) for up to 96 weeks. Resuming ART was not associated with a decline in these scores for up to 45 weeks.

DOI10.1212/WNL.0b013e3181d9ed09
Alternate JournalNeurology
PubMed ID20237308
PubMed Central IDPMC2860482
Grant List1 R01 MH085597-01A1 / MH / NIMH NIH HHS / United States
1 R34 AI084553-01 / AI / NIAID NIH HHS / United States
1U01-AI069484 / AI / NIAID NIH HHS / United States
1U01AI068636 / AI / NIAID NIH HHS / United States
1U01AI069428-01 / AI / NIAID NIH HHS / United States
1U01AI069532-01 / AI / NIAID NIH HHS / United States
1U19AI082608-01 / AI / NIAID NIH HHS / United States
3 U01 AI046376-05 / AI / NIAID NIH HHS / United States
5 T32 AI007151-31 / AI / NIAID NIH HHS / United States
5 U01 AI069423-03 / AI / NIAID NIH HHS / United States
5 U01 NS032228 / NS / NINDS NIH HHS / United States
5 U01-AI067854-04 / AI / NIAID NIH HHS / United States
5-MO1 RR00044 / RR / NCRR NIH HHS / United States
5-P30-AI-045008-07 / AI / NIAID NIH HHS / United States
5U01AI032782 / AI / NIAID NIH HHS / United States
AI-069513 / AI / NIAID NIH HHS / United States
AI-68636 / AI / NIAID NIH HHS / United States
AI068634 / AI / NIAID NIH HHS / United States
AI069423-01 / AI / NIAID NIH HHS / United States
AI069423-03 / AI / NIAID NIH HHS / United States
AI069424 / AI / NIAID NIH HHS / United States
AI069432 / AI / NIAID NIH HHS / United States
AI069434 / AI / NIAID NIH HHS / United States
AI069467-01 / AI / NIAID NIH HHS / United States
AI069470-01 / AI / NIAID NIH HHS / United States
AI069471 / AI / NIAID NIH HHS / United States
AI069472 / AI / NIAID NIH HHS / United States
AI069494-01 / AI / NIAID NIH HHS / United States
AI069495-01 / AI / NIAID NIH HHS / United States
AI069511-01 / AI / NIAID NIH HHS / United States
AI25859 / AI / NIAID NIH HHS / United States
AI27661 / AI / NIAID NIH HHS / United States
AI46370 / AI / NIAID NIH HHS / United States
AI50410 / AI / NIAID NIH HHS / United States
K24 AI051982 / AI / NIAID NIH HHS / United States
K24 AI51982 / AI / NIAID NIH HHS / United States
M01 RR00047 / RR / NCRR NIH HHS / United States
M01-RR00096 / RR / NCRR NIH HHS / United States
P01 HD059454 / HD / NICHD NIH HHS / United States
P30 AI050410 / AI / NIAID NIH HHS / United States
P30 AI27763 / AI / NIAID NIH HHS / United States
R01 AI051219 / AI / NIAID NIH HHS / United States
R01 MH067751 / MH / NIMH NIH HHS / United States
R01 MH081772 / MH / NIMH NIH HHS / United States
RR00046 / RR / NCRR NIH HHS / United States
T32 AI060530 / AI / NIAID NIH HHS / United States
U01 AI062677 / AI / NIAID NIH HHS / United States
U01 AI069423 / AI / NIAID NIH HHS / United States
U01 AI069502 / AI / NIAID NIH HHS / United States
U0I-AI069556 / AI / NIAID NIH HHS / United States
U62 CCU123541 / / PHS HHS / United States